论文部分内容阅读
丙型肝炎是由丙型肝炎病毒(HCV)引起的一种隐匿性、持续性、进展性疾病,每年新发感染300万~400万例,慢性化率高达75%~85%;感染25~30年后发展为肝硬化的比例5%~25%;肝硬化患者肝癌年发生率1%~7%。因此,及早发现并给予有效地抗HCV治疗是治疗丙型肝炎的关键。目前,干扰素联合利巴韦林为治疗丙型肝炎的标准方案。近年来,对丙型肝炎抗病毒治疗的药物及使用人群均有较多研究。现就慢性丙型肝炎抗病毒治疗新进展介绍如下。
Hepatitis C is an occult, persistent and progressive disease caused by Hepatitis C virus (HCV). Each year, new infections range from 3 million to 4 million and the rate of chronicity is as high as 75% -85% 30 years after the development of cirrhosis of the ratio of 5% to 25%; liver cirrhosis patients with annual incidence of 1% to 7%. Therefore, early detection and effective anti-HCV treatment is the key to the treatment of hepatitis C. Currently, interferon plus ribavirin is the standard treatment for hepatitis C. In recent years, hepatitis C antiviral drugs and the use of the population have more research. The new progress on chronic hepatitis C antiviral therapy is introduced below.